The recent development of the first disease-modifying drug for Alzheimer's disease
represents a major advancement in dementia treatment. Behind this breakthrough is a …

Background: The characterizing symptom of Alzheimer disease (AD) is cognitive
deterioration. While much recent work has focused on defining AD as a biological construct …

Background: Graph theory and connectomics are new techniques for uncovering disease-
induced changes in the brain's structural network. Most prior studied have focused on …

It is important to characterize the temporal trajectories of disease-related biomarkers in order
to monitor progression and identify potential points of intervention. These are especially …

Kognitiivinen ikääntyminen kuuluu läpi elämän tapahtuviin muutoksiin muistissa ja muissa
tiedon käsittelyyn liittyvissä toiminnoissa. Monet kognition osaalueet alkavat heiketä jo …

Mixed models for repeated measures (MMRMs) are ubiquitous when analyzing outcomes of
clinical trials. However, the linearity of the fixed‐effect structure in these models largely …

Background. Alzheimer's disease (AD) is a major public health concern, and there is an
urgent need to better understand its complex biology and develop effective therapies. AD …

Locus coeruleus (LC) tau accumulation begins early. Targeting LC (dys) function might
improve early identification for Alzheimer's disease (AD) risk. Pupillary responses during …

Quantitative characterization of disease progression using longitudinal data can provide
long-term predictions for the pathological stages of individuals. This work studies the robust …

Abstract Background Stage 1 of the National Institute on Aging–Alzheimer's Association's
proposed Alzheimer's disease continuum is defined as amyloid-β (Aβ) positive but …